---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-116023"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:48:46.718030+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# NeuroBo closes $32.3M financing and licenses NASH/obesity drugs from Dong-A

## Summary
- Public offering grossed ~$17.3M (full over-allotment); private placement $15M from Dong-A; net proceeds ~$15.1M.
- Exclusive license for DA-1241 (NASH) and DA-1726 (obesity/T2D); NeuroBo holds global rights ex-Asia Pacific.
- Issued 3.1M common shares, 2.6M Series B preferred shares, and warrants for up to 11.5M common shares.
- Warrants exercisable at $3.00 after stockholder approval; meeting expected by Dec 22, 2022.
- Preferred stock has no dividend rights, no liquidation preference, and limited voting rights.

## SEC filing metadata
- accession: 0001104659-22-116023
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 3.03, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000110465922116023/0001104659-22-116023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000110465922116023/tm2225873d12_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-116023
- JSON: https://secwatch.observer/filing/0001104659-22-116023.json
- Plain text: https://secwatch.observer/filing/0001104659-22-116023.txt

## Key facts
- Governance Changes
  MetaVia Inc.: Filed Certificate of Designations for Series A and Series B Convertible Preferred Stock (effective 2022-11-04).
  - Change: charter amendment
  - Effective: 2022-11-04
  source text: On November 4, 2022, the Company filed the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the “ Series A Certificate of Designations ”) and the Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (the “ Series B Certificate of Designations ,” and together with the Series A Certificate of Designations, the “ Certificate of Designations ”) with the Secretary of State of the State of Delaware.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1638287/000110465922116023/0001104659-22-116023-index.htm
- Material Agreements
  MetaVia Inc. entered into Underwriting Agreement with Ladenburg Thalmann & Co. Inc. valued at net proceeds approximately $15.1 million (effective 2022-11-04).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Ladenburg Thalmann & Co. Inc.
  - Value: net proceeds approximately $15.1 million
  - Effective: 2022-11-04
  source text: On November 4, 2022, NeuroBo Pharmaceuticals, Inc. (the “ Company ”) entered into an Underwriting Agreement (the “ Underwriting Agreement ”) with Ladenburg Thalmann & Co. Inc. (the “ Underwriter ”), pursuant to which the Company issued and sold, in an underwritten public offering by the Company (the “ Public Offering ”), (a) 2,397,003 Class A Units (the “ Class A Units ”), with each Class A Unit consisting of (i) one share of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), (ii) one warrant to purchase one share of Common Stock exercisable following approval of the Company’s stockholders (each, a “ Series A Warrant ”) and (iii) one warrant to purchase one share of Common Stock exercisable following approval of the Company’s stockholders (each, a “ Series B Warrant ,” and together with the Class A Series A Warrants, the “ Warrants ”), with each Class A Unit offered to the public at an offering price of $3.00 per Class A Unit and (b) 2,602,997 Class B Units
  evidence_url: https://www.sec.gov/Archives/edgar/data/1638287/000110465922116023/0001104659-22-116023-index.htm
- Material Agreements
  MetaVia Inc. entered into Warrant Agency Agreement with American Stock Transfer & Trust Company LLC valued at governs warrants sold in Public Offering (effective 2022-11-08).
  - Action: entry
  - Counterparty: American Stock Transfer & Trust Company LLC
  - Value: governs warrants sold in Public Offering
  - Effective: 2022-11-08
  source text: On November 8, 2022, the Company also entered into a warrant agency agreement with the Company’s transfer agent, American Stock Transfer & Trust Company LLC, who will act as warrant agent for the Company, setting forth the terms and conditions of the Warrants sold in the Public Offering (the “ Warrant Agency Agreement ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1638287/000110465922116023/0001104659-22-116023-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.